Based on the Phase II data, Imbria Pharmaceuticals’ inerafaxstat could complement existing treatments rather than replace them.

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

The Ukrainian government has instigated rapid cost-cutting measures across the drug retail sector, triggered by reports of ...

For cell and gene therapy, a consistent supply of quality starting material is vital that is maintained throughout the ...

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Completed biopharma IPOs that raised more than $100 million saw a twofold increase during the year. Biopharmaceutical initial ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

Download our guide to the digital therapeutics landscape, key providers, and market trends. Discover how digital health solutions can enhance pharmaceutical outcomes.

The Weill Cancer Hub East has been established to explore the “interplay” between nutrition and immunotherapy in cancer ...